CSE: BUX | OTCQB: BMKDF | FSE: 20B
News Releases
Discover the latest news, announcements, and events showcasing BioMark's innovations and solutions across the entire cancer care pathway.
BioMark Announces Participation in upcoming MSACL 2026 and BIOHorizon 2026 Life Sciences Conferences
BioMark Diagnostics Inc. announces its upcoming participation in two premier Canadian life sciences events: MSACL 2026 and BIOHorizon 2026 . The company will present advances in its metabolomics-based liquid biopsy platform, showcase high-throughput mass spectrometry collaborations with Sciex and Phytronix, and join panel discussions on translating clinical biomarkers from lab to bedside
BioMark’s Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy
BioMark Diagnostics reports five peer-reviewed publications in nine months validating its metabolomics liquid biopsy for early NSCLC detection. New studies show high accuracy (up to 96.9% ROC-AUC), compact AI/ML panels, and strong cost efficiency while reducing smoking-related confounding.
BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day
BioMark Diagnostics endorses the 2026 World Lung Cancer Day global call for equitable access to early screening. The company advances its metabolomics-based liquid biopsy platform, validated in Quebec and the HANSE study in Germany, to help reduce barriers to earlier detection.
BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test
BioMark Diagnostics receives formal patent allowances from CIPO (Canada) and the EPO (Europe) for its early-stage lung cancer blood test. The metabolomics platform and algorithm are validated across more than 15,000 samples from Quebec, France, and Germany.
BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform
BioMark Diagnostics receives a USPTO Notice of Patent Allowance for Application No. 18/304,741 covering urine-based detection of lung cancer using polyamine metabolites and mass spectrometry, expanding its liquid biopsy platform beyond blood into non-invasive alternative biofluids.
BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum
BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum BioMark Comprehensive Metabolomics Assay Selected asTop Canadian Innovation for the CTS